NSE-listed pharmaceutical companies offering contract development and manufacturing (CDMO) services for APIs, intermediates, and drug products — India's growing role as the world's pharmacy of choice.
Sectors represented: Healthcare
RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. . Risingshareofbiologicsalongwithincreasinginvestmentsin. biologicsfornewnichemodalities CDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. .
Our comprehensive and. customized services for Drug Substances (DS) and Drug. Products (DP) offer innovative solutions to ensure timely. and safe drug development. rs at every. stage of drug development. Our comprehensive and. customized services for Drug Substances (DS) and Drug. Products (DP) offer innovative solutions to ensure timely. and safe drug development. We conduct custom synthesis.
Robust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business. 17 obust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business...
DCGI approvals. 1. , along with. 923 FSSAI approvals. 150. 4. 925+. 3. (1) As of 31st March 2024; (2) As of 1st Aug 2024. Domestic Branded Formulations. 59. th. Rank in Indian Branded. Formulations. 1. 140. Brands. 69%. Chronic and. sub-chronic segment. 1. 1.5k+. Salesforce. Exports Oriented Branded Formulations. 179. 246. 134. 289. Mar’22Mar’23Mar’24. Under Registration. Dossiers.
CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS). ❏EHS and Quality are the highest priority. nue. CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS).
This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. locate resources. more effectively toward innovation and commercial. growth. This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. By leveraging CDMOs' streamlined procedures.
Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3. 5.0. 5.6. 6.2. 7.1. 8.2. 9.5. 10.8 920242029F. Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3.
APIs with low competitive intensity. Ongoing augmentation of new. product pipeline. Built deep cost position through. backward integration. Top 3 player in 8 out of 10 top. molecules in the API portfolio. Formulation: : Offering end to end. vertically integrated solutions. including pellets and formulations. for partners. We have more nearly 50 product. families in the APIs and formulation.
Process DevelopmentQuality & Regulatory ServicesDrug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced. contamination risk and higher uptime. . Clinical batches to high-speed commercial. lines inc. ug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced.
Transplant & Immuno. Isacrest. TM. 18. Trusted CDMO partner for Fermentation & Semi-Synthetic API’s. CDMO Overview. Provide contract research and manufacturing. services for developing APIs and formulations. Prioritizes innovation, backed by a DSIR-. certified R&D facility with a team of 180+ tic API’s. CDMO Overview. Provide contract research and manufacturing.